Pimobendan Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a benzimidazole-pyridazinone derivative used as the active pharmaceutical ingredient for veterinary cardiology dose forms. The molecule has the molecular formula C19H18N4O2, a relative molecular mass of 334.37 g/mol, and the Chemical Abstracts Service registry number 74150-27-9. The substance is supplied as a white to off-white crystalline powder. Grade designations are assigned by the manufacturer according to particle size tier, residual solvent profile, and microbial quality, most commonly as micronized, standard, and low-endotoxin grades. The API is intended for further pharmaceutical processing under current good manufacturing practice; it is not a finished veterinary medicinal product. Pharmacopoeial alignment is expressed with reference to Ph. Eur. 2034 for substances for pharmaceutical use. Batch documentation may be supported by a drug master file or active substance master file. In tablet, capsule, powder, granule, premix, and solution applications, the selected pimobendan grade is determined by the route of administration, the manufacturing process, and the requirement for dissolution, blend homogeneity, injectability, or stability under feed-matrix conditions.

How does pimobendan modulate cardiac function in the target species?

Mechanistically, pimobendan is classified as an inodilator. Its principal pharmacological actions are calcium sensitisation of cardiac troponin C and inhibition of phosphodiesterase III. The calcium-sensitising effect increases contractile force for a given systolic calcium transient, which differentiates it from beta-adrenergic agonists that increase intracellular calcium and cyclic AMP. The PDE III inhibition contributes to vasodilation and reduces ventricular afterload. In dogs, this combination improves forward stroke volume and reduces left atrial and pulmonary venous pressures in congestive heart failure. The 2019 ACVIM consensus statement on myxomatous mitral valve disease identifies pimobendan as a treatment component in dogs with clinical heart failure and in selected preclinical cases with cardiomegaly. The EPIC trial in dogs with preclinical myxomatous mitral valve disease and echocardiographic cardiomegaly reported a longer time to the primary composite endpoint in the pimobendan group than in the placebo group. The usual oral dose is 0.25–0.30 mg/kg every 12 hours, administered on an empty stomach or approximately 1 hour before food because food reduces bioavailability. Injectable dose forms are less commonly specified in regulatory dossiers, and the published stability window for aqueous pimobendan solutions is limited; formulation-specific forced degradation studies are therefore mandatory.

For oral solid dosage forms, micronized pimobendan is typically produced by jet milling with compressed air or nitrogen at a feed pressure of 6–8 bar. The milled material is characterised by laser diffraction according to Ph. Eur. 2.9.31 or USP <429>. Because pimobendan is practically insoluble in aqueous media, dissolution from tablets and capsules is strongly influenced by particle size distribution. The micronized grade is blended with silicified microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate. Blend uniformity is verified by Ph. Eur. 2.9.40 or USP <905>, with an acceptance value of 15 or less for single-dose preparations. Tablets are compressed on a rotary press with precompression; friability is controlled to less than 1.0% per Ph. Eur. 2.9.7, and hardness is adjusted to 40–80 N depending on tablet shape and diameter. If the tablet is a scored veterinary tablet, the score line is validated by mass uniformity across split halves. Wet granulation may be used when the blend has poor flow or when higher drug load is required. A high-shear granulator is used with impeller and chopper speeds established by torque and granule growth studies, followed by fluid-bed drying at 50–60 °C until loss on drying is below 2.0%. Processing at higher inlet temperatures should be avoided because thermal degradation can increase total related substances.

Compendial specification and impurity profile

The analytical release programme must distinguish pharmaceutical-grade pimobendan from technical-grade or research-grade material. The HPLC assay method is validated for specificity, linearity, accuracy, and precision, and it uses a reference standard qualified against the pharmacopoeial standard. Impurity controls follow ICH Q3A. Because the maximum daily dose of pimobendan in the target species is below 1 g, an identification threshold of 0.10% applies in routine control. The following specification profile represents a typical pharmaceutical-grade release programme.

Residual solvent control is performed by headspace gas chromatography. If dimethylformamide is used in the upstream synthesis, the Class 2 limit is 880 ppm; for dichloromethane, the limit is 600 ppm; for methanol, the limit is 3000 ppm. These limits follow ICH Q3C. Elemental impurities are assessed following ICH Q3D; the concentration limits are calculated from the permitted daily exposure and the maximum daily dose of pimobendan in the target species. Water content determined by Karl Fischer titration is typically not more than 0.5%. X-ray powder diffraction is used to confirm polymorph identity, and differential scanning calorimetry may be included to monitor melting endotherm reproducibility. Batch-to-batch variability in residual solvent profile, particle size, and polymorphic identity is a recognised supply-chain failure mode; certificates of analysis should be compared against the approved dossier before use in commercial batches.

When the API is formulated into aqueous injection vehicles, pH, light exposure, and particulate matter define the usable boundary

Injectable dose forms require a low-endotoxin pimobendan grade with documented bioburden and endotoxin data. The free base is practically insoluble in water; therefore injectable solutions may be prepared in an acidified aqueous vehicle, a co-solvent system containing propylene glycol and water, or a cyclodextrin complex. If pH is used for solubilisation, the final pH should remain in the range where the API remains dissolved during storage at 2–8 °C and room temperature; this boundary must be established experimentally because published data for this specific configuration is limited. Aseptic filtration through a 0.22 µm sterilizing-grade membrane is preferred over terminal steam sterilisation because the compound may undergo hydrolytic degradation under moist heat. The solution is filled into amber glass or opaque plastic containers to limit photodegradation. Particulate matter is tested by Ph. Eur. 2.9.19 or USP <788>. Endotoxin testing is performed by kinetic turbidimetric or gel-clot methods per Ph. Eur. 2.6.14; the limit is derived from the maximum intended dose per kilogram. Sterility testing follows Ph. Eur. 2.6.1. Osmolality should be controlled when the injection is administered intravenously; a hyperosmotic solution can cause injection-site pain and thrombophlebitis. If the formulation contains propylene glycol, the concentration should not exceed accepted parenteral tolerance limits for the target species, and batch records should document actual osmolality. At relative humidity above 60%, pre-drying of the API is recommended before weighing for moisture-sensitive processes.

For capsules, powders, granules, and premixes, the standard powder grade is often selected because the micronized grade can become cohesive and may require a glidant. Capsules are prepared by blending the standard or micronized grade with colloidal silicon dioxide at 0.5–1.0% w/w, followed by dilution with lactose monohydrate or microcrystalline cellulose. A low-shear V-blender or bin blender is used, and mixing time is established by blend sampling at 10 or more points. If the coefficient of variation for assay is above 5.0%, segregation or particle size mismatch should be investigated, and the blend is reprocessed or reformulated. Capsule filling on a dosator or tamping-pin machine is preferred for low-dose powders because these machines reduce powder segregation. Content uniformity is performed by Ph. Eur. 2.9.40 or USP <905>. Oral powders and granules are produced by geometric dilution or by carrier adsorption onto lactose monohydrate or corn starch. Ribbon blenders and tumble blenders are operated at low speed to avoid attrition of the carrier. Homogeneity is determined by assay at multiple sampling points; a typical acceptance criterion is 90–110% of label claim with RSD no more than 5.0%. Premixes for feed application require additional stability evaluation because feed matrices contain moisture, transition metals, and organic acids that can accelerate degradation or bind the API. The premix should be stored in a dry environment below 25 °C and protected from light. Extemporaneous oral solutions and suspensions are prepared by dispensing the API into a vehicle containing a suspending agent such as sodium carboxymethylcellulose or a co-solvent such as propylene glycol. These preparations should be assigned a short shelf life based on stability data; no standard default beyond-use date should be assumed. Avoid strongly alkaline buffers, which can precipitate the free base, and avoid oxidising agents, which can form degradation products. Cleaning validation in a multi-product facility is critical because pimobendan is active at low doses; carryover limits are calculated from the clinical dose and the acceptance criteria of the next product, and cleaning verification by swab sampling should be performed after each campaign.

Why this grade differs from unprocessed pimobendan and alternative inotropic APIs

Differences between this veterinary API and research-grade pimobendan are defined by residual solvent profile, impurity identification and quantification, particle engineering, polymorphic consistency, and regulatory documentation. Research-grade material may have no defined particle size distribution, unknown residual solvents, and no impurity qualification; pharmaceutical-grade material is manufactured under ICH Q7 and released with a validated specification. The micronized grade improves dissolution in tablets but may increase cohesiveness and static charging. The standard grade disperses more easily in premix granulation, and the low-endotoxin grade is required for injectable applications. Compared with alternative inodilators, pimobendan has a different pharmacological signature. Dobutamine is a parenteral beta-adrenergic agonist that increases myocardial oxygen consumption and requires continuous infusion. Milrinone is a PDE III inhibitor with no calcium-sensitising component; its clinical use is largely acute or short term. Digoxin is a narrow-therapeutic-index Na+/K+-ATPase inhibitor with different toxicity management. Pimobendan can be administered orally twice daily for chronic management and provides both positive inotropy and vasodilation through dual mechanisms. Within pimobendan lots, the major sources of batch-to-batch variation are particle size distribution, polymorphic identity, residual solvent levels, and moisture content. A supplier change should trigger comparability assessment per ICH Q5E or applicable veterinary guidance, including analytical profile and stability comparison. If the API is exposed to humidity above 60% RH, pre-drying at 40 °C for 4 hours may be used only after confirming no effect on impurity profile and polymorph identity. The product should not be blended with strong oxidising agents, and alkaline aqueous media above the solubility limit should be avoided.